Resonance Health (RHT) specialises in the development and commercialisation of magnetic resonance imaging (MRI) related technology, headquartered in Perth, Western Australia.

Our lead product is FerriScan^®, a medical technology for the non-invasive measurement of liver iron concentration. FerriScan is being used for both the detection and monitoring of iron overload.

Disorders of iron metabolism are amongst the most common diseases in the world. Hereditary Hemochromatosis is a condition where excessive uptake of dietary iron leads to accumulation of iron and affects around 1 in 227 people of Northern European decent.

Additionally, iron accumulates due to repeated blood transfusions in patients with blood disorders such as ß-thalassemia, sickle cell anaemia and myelodysplastic syndrome (MDS). FerriScan is being used extensively in a number of clinical trials investigating the effects of iron chelation in populations of patients who present with signs of iron overload due to repeated blood transfusions.

Excess iron deposits in tissues of the body, particularly the liver, eventually causing tissue damage and organ failure. For patients affected with iron overload, accurate monitoring of the body iron burden is crucial to the management of their disease.

The key clinical benefits of FerriScan include:

• Provision of an accurate non-invasive liver iron concentration measurement.
• Assistance in definitive iron overload diagnosis.
• Ability to achieve optimum treatment matched to the exact level of iron overloading.

FerriScan is the first non-invasive test for liver iron concentration to have achieved regulatory clearances in the US, Canada, Europe, Australia and NZ. To see where FerriScan is available, click on the link below.

FerriScan Locations

Should you have any questions about FerriScan please contact the company on info@ferriscan.com.